CLNN FDA Accelerated Approval NDA for ALS CNM-Au8 NfL Surrogate Biomarker Phase 3 2027 Study
Clene Inc. Common Stock · PHARMACEUTICAL PREPARATIONS · Now $6.11
-20% in 7d after detection
Post-detection moves
1h
—
1d
-19%
3d
-8.7%
7d
-20%
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS